WELCOME TO ZYLERIS PHARMATECH
Zyleris provides topical formulation development services. Specifically, we provide high-throughput topical formulation screening and development services. Our first-in-class, high-throughput Franz Cell platform was developed based on Franz Cell principle. It offers the best of both worlds - speed, and cost efficiency associated with high-throughput experimentation, and data compatibility with standard Franz Cell technology.
Topical Formulation Screening and Development
Faster, Cheaper, and Better
Tissue Permeation (IVPT)Any type of tissue absorption and penetration studies can be conducted on our High Throughput Franz Cell platform.
IVRTIVRT method development and test conducted at Zyleris are in full compliance with FDA SUPAC-SS guidance.
Topical Formulation DevelopmentBased on physical and chemical properties of your compounds, select the dosage form most suitable for the compounds and intended indications - serums, ointments, gels, lotions, creams, etc.
Through technology innovations, Zyleris strives to deliver values in topical product development to our clients. Technologies help us to find faster, cheaper, and better way to develop superior topical formulations.
High-Throughput Franz Cell TechnologyZyleris has developed a first-in-class, high-throughput Franz Cell technology platform. This technology is developed based on the Franz Cell principle. It offers the best of both worlds - speed, cost efficiency associated with high-throughput experimentation, and data compatibility with the industry standard Franz Cell technology.
API Release EnhancementPetrolatum-based formulations have many advantages for topical delivery of APIs, such as formulation of occlusive coating and emollient properties. These are particularly desirable for products intended for treatment of bacterial and fungal infection, atopic dermatitis, psoriasis, and wound dressing.
Novel IVRT TechnologyDevelopment of IVRT methods for ointments or other lipophilic semisolids is very challenging. It is particularly challenging when the API is hydrophilic or the product is a combo formulation. Zyleris has developed a patent-pending technology that can be used routinely to develop IVRT methods for these “difficult” formulations.
- 2017 AAPS MeetingZyleris exhibited at the 2017 AAPS Meeting on November 13-15 at the San Diego Convention Center. Our booth is #2438. […]
- 2017 ContractPharma 16th Annual Contracting and Outsourcing Conference and Tabletop ExhibitionZyleris exhibited at 2017 ContractPharma 16th Annual Contracting and Outsourcing Conference and Tabletop Exhibition on September 14-15 at the Hyatt Regency in New Brunswick, NJ. Our table is #64. […]
- High-Throughput Screening of Compound Library for Topical and Transdermal DeliveryChicago, IL, U.S.A, April 27, 2011 – Zyleris PharmaTech (www.Zyleris.com) has announced the launch of a new drug development service: high-throughput screening of compound library to identify drug candidates for topical and transdermal delivery. The screening service utilizes Zyleris’ Franz Cell-based high-throughput technology. Each screening system consists of a compact 108-cell screening station with flexibility for both absorption and penetration studies. The system is fully validated […]
- High-Throughput Formulation Screening Service for Topical and Transdermal Drug DevelopmentChicago, IL, U.S.A, July 26, 2010 – Zyleris PharmaTech (www.Zyleris.com) has announced today the launch of its high-throughput formulation screening service for topical and transdermal drug development based on the company’s innovative experimentation technology. Zyleris’ technology is designed to transform topical and transdermal drug development. The technology utilizes Franz Cell principle in a high-throughput fashion, which is at least 20x faster than present industrial standard Franz Cell […]